186 related articles for article (PubMed ID: 36943311)
1. Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor positron emission tomography/computed tomography imaging in real-life setting.
Kostiainen I; Majala S; Schildt J; Parviainen H; Kauhanen S; Seppänen H; Miettinen PJ; Matikainen N; Ryhänen EM; Schalin-Jäntti C
Eur J Endocrinol; 2023 May; 188(5):421-429. PubMed ID: 36943311
[TBL] [Abstract][Full Text] [Related]
2. Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.
Mennetrey C; Le Bras M; Bando-Delaunay A; Al-Mansour L; Haissaguerre M; Batisse-Lignier M; Ouvrard E; Ansquer C; Walter T; de Mestier L; Kelly A; Tlili G; Giraud S; North MO; Odou MF; Goichot B; Cuny T; Loundou A; Romanet P; Imperiale A; Taïeb D
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2056-e2064. PubMed ID: 34940846
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
4. Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.
Said M; Krogh J; Feldt-Rasmussen U; Rasmussen ÅK; Kristensen TS; Rossing CM; Johannesen HH; Oturai P; Holmager P; Kjaer A; Klose M; Langer S; Knigge U; Andreassen M
J Neuroendocrinol; 2023 Aug; 35(8):e13322. PubMed ID: 37564005
[TBL] [Abstract][Full Text] [Related]
5. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
7. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.
van Beek DJ; Pieterman CRC; Wessels FJ; van de Ven AC; de Herder WW; Dekkers OM; Zandee WT; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
Front Endocrinol (Lausanne); 2022; 13():926491. PubMed ID: 36277719
[TBL] [Abstract][Full Text] [Related]
9. The Impact of
Cuthbertson DJ; Barriuso J; Lamarca A; Manoharan P; Westwood T; Jaffa M; Fenwick SW; Nuttall C; Lalloo F; Prachalias A; Pizanias M; Wieshmann H; McNamara MG; Hubner R; Srirajaskanthan R; Vivian G; Ramage J; Weickert MO; Pritchard DM; Vinjamuri S; Valle J; Yip VS
Front Endocrinol (Lausanne); 2021; 12():654975. PubMed ID: 34163434
[TBL] [Abstract][Full Text] [Related]
10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
11. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract][Full Text] [Related]
13. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
14. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
15. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK
World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
[TBL] [Abstract][Full Text] [Related]
16. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma.
Serfling SE; Zhi Y; Megerle F; Fassnacht M; Buck AK; Lapa C; Werner RA
Endocrine; 2022 Oct; 78(1):169-176. PubMed ID: 35751778
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
19. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
20. Expression of p27
Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]